Andrea Mayer-Mokler

Company: Immatics

Job title: Vice President & Global Head of Clinical Sciences

Seminars:

ACTengine IMA203 & IMA203CD8 TCR-T Cell Therapy Targeting PRAME in Solid Tumor Patients 8:30 am

• Phase 1b clinical data on IMA203 demonstrate deep and durable responses in heavily pretreated metastatic melanoma patients at RP2D • Next-generation IMA203CD8 Phase 1a dose escalation data show enhanced pharmacology and potency per cell; to be evaluated for future in development in solid cancers with medium-level PRAME copy numbers • SUPRAME, randomized-controlled Phase 3…Read more

day: Day 1

Industry Leaders’ Fireside Chat: A Commercial TCR-T & TCR Bispecific – What’s Next? 2:15 pm

• Reflecting on the past: celebrating the first TCR-T commercial approval and its impact on the field, along with novel clinical data • Determining the current state of play: discussing what challenges remain, the current funding environment and the priority for the field to outline present focus • What’s next? Discussing the potential for allogeneic…Read more

day: Day 1